

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2023.

Commission File Number: 001-40627

**SOPHiA GENETICS SA**  
(Exact name of registrant as specified in its charter)

La Pièce 12  
CH-1180 Rolle  
Switzerland  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

## SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**SOPHIA GENETICS SA**

Date: August 14, 2023

By: /s/ Daan van Well  
Name: Daan van Well  
Title: Chief Legal Officer

---

EXHIBIT INDEX

Exhibit No.	Description
99.1	Informative slides SOPHiA GENETICS for UBS Conference dated August 15, 2023

---



# Democratizing Data-Driven Medicine

**Ross Muken**

Chief Financial Officer & Chief Operating Officer

August 15, 2023



# Cautionary Notices

This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this presentation. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this presentation to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

## No offer to sell or buy

This presentation does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

## Other material information

This presentation does not contain all material information about SOPHiA GENETICS SA and its subsidiaries. No representations or warranties (expressed or implied) are made regarding the completeness of the information contained in this presentation. Refer to our Securities and Exchange Commission filings for additional information about us.

## Market and industry data

This presentation contains industry, market and competitive position data that are based on general and industry publications, surveys and studies conducted by third parties, some of which may not be publicly available, and our own internal estimates and research. Our estimates of addressable market (or similar concepts) are primarily based on epidemiological data, including incidence and prevalence estimates of addressable populations, as well as a range of price assumptions for our products taking into account differences in panel sizes, which may change over time. Third-party publications, surveys and studies generally state that they have obtained information from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. While we are not aware of any misstatements regarding the industry, market and competitive position data presented herein, these data involve a number of assumptions and limitations and contain projections and estimates of the future performance of the industries in which we operate that are subject to a high degree of uncertainty.

## Research use only

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information included in this presentation is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [support@sophiagenetics.com](mailto:support@sophiagenetics.com) to obtain the appropriate product information for your country of residence.

## Snapshot of SOPHIA GENETICS



We are a category defining software company on a mission to  
**Democratize Data-Driven Medicine**

The information on this slide is as of 06/30/2023.

# The Emergence of the Cloud and AI

have transformed countless of industries



BUT,  
**Healthcare**  
is lagging








# Creating Network Effects in Healthcare is Difficult

given non-standardized methods and sensitive data



# Significantly Important for Key Diseases

driven by genomic alterations

## Cancer


>25 Million New  
Cancer Cases per Year<sup>1</sup>

## Rare Diseases

~5% of the global population  
suffers from a Rare Disease<sup>2</sup>


# New Data Modalities Bring Objectivity

into human biology and diseases




# Applying AI to Genomic Data

HRD example for PARP inhibitors




# Applying AI to Multimodal Data

NSCLC example for Immunotherapy




# Our Ability to Deliver Healthcare Solutions

Built on collective intelligence from our global network



- Generate robust insights
- Break data silos
- **Create a collective intelligence**
- Accelerate adoption of precision medicine



# Growing with our Customer's Volume


via a consumption based SaaS model






# A Look into a Customer's Expansion Journey

as volume and the number of applications increase



# Importantly, Customer Growth Accelerates as they get Larger



Note: Based on recurring platform customers. FN 1: Represents CAGR of total tier revenue of customers with \$100K+ in revenue and CAGR of total tier revenue of customers with \$0 - \$100K in revenue.  
© SOPHIA GENETICS 2023

## Key Financial Metrics

**750+**

Total customers <sup>(1)</sup>

**430+**

Core Genomics customers <sup>(1)</sup>

**1.4 million+**

Genomic Profiles Analyzed <sup>(5)</sup>

**~78,000+**

Genomic profiles analyzed in 2Q 2023<sup>(1)</sup>

**30% - 35%**

2023 constant currency ex COVID revenue growth guidance  
as of August 8, 2023 <sup>(2,4)</sup>

**30%**

2Q2023 constant currency ex COVID revenue growth <sup>(3)</sup>

**67% | 70%**

Q2 2023 IFRS gross profit margin | adjusted gross profit margin <sup>(3)</sup>

**~\$149M**

Cash, cash equivalents, & term deposits <sup>(1)</sup>

**FN 1:** Represents statistic as of 06/30/2023. **FN 2:** The Company is unable to provide a reconciliation of forward-looking constant currency revenue growth excluding COVID-19-related revenue to Revenue, the most comparable IFRS financial measure, due to the inherent difficulty in forecasting and quantifying the impact of foreign currency translation. **FN 3:** Please refer to appendix for non-IFRS reconciliation. **FN 4:** Represents financial outlook as of August 8, 2023. This presentation does not represent an update or affirmation of previously disclosed guidance. **FN 5:** Represents statistic as of 06/30/2023.



**Thank You**



## Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin

for the Three Months Ended June 30, 2023

Amounts in USD thousands

(unaudited)

Three months ended June 30, 2023

Revenue	\$15,054
Cost of revenue	(5,007)
Gross profit	\$10,047
Amortization of capitalized research and development expenses <sup>(1)</sup>	496
Adjusted gross profit	\$10,543
Gross profit margin	67%
Amortization of capitalized research and development expenses <sup>(1)</sup>	3%
Adjusted gross profit margin	70%

## Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth and Constant Currency Revenue Growth Excluding COVID-19-Related Revenue

(Amounts in USD thousands)	2022	2023
	Q2	Q2
<b>Revenue</b>		
<b>Reported Revenue</b>	<b>\$11,667</b>	<b>\$15,054</b>
<i>Y-o-Y Growth</i>		29%
Current Period Constant Currency Impact		(202)
<b>Constant Currency Revenue</b>	<b>\$11,667</b>	<b>\$14,852</b>
<i>Y-o-Y Growth</i>		27%
COVID-19 Revenue	(292)	(72)
Constant Currency Impact on COVID-19 Revenue		(8)
<b>Constant Current Revenue Excluding COVID-19 Revenue</b>	<b>\$11,375</b>	<b>\$14,772</b>
<i>Y-o-Y Growth</i>		30%

## Notes to the Reconciliation of IFRS to Adjusted Financials

- (1) Amortization of capitalized research and development expenses consists of software development costs amortized using the straight-line method over an estimated life of five years. These expenses do not have a cash impact but remain a recurring expense generated over the course of our research and development initiatives.

# Consistent Growth in Analysis Volume

accelerated momentum of analysis volume conducted on our platform in 1H 2023

